279 POSTER MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72213-4 ◽

2008 ◽

Vol 6 (12) ◽

pp. 90 ◽

Author(s):

A. Cervantes ◽

T. Macarulla ◽

S. Roselló ◽

E. Rodríguez-Braun ◽

J. Baselga ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Aurora A Kinase ◽

Download Full-text

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

281 POSTER Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72215-8 ◽

2008 ◽

Vol 6 (12) ◽

pp. 91 ◽

Author(s):

E. Dees ◽

J.R. Infante ◽

R.B. Cohen ◽

B. O'Neil ◽

H. Burris ◽

...

Keyword(s):

Phase I ◽

Pharmacokinetic Study ◽

Selective Inhibitor ◽

Aurora A Kinase ◽

Download Full-text

Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostrate Cancer Commonly Remains Hormone Driven

European Urology ◽

10.1016/j.eururo.2009.04.017 ◽

2009 ◽

Vol 56 (1) ◽

pp. 220 ◽

Author(s):

Nicholas J. Vogelzang

Keyword(s):

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Prostrate Cancer ◽

Castration Resistant

Download Full-text

Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

European Urology ◽

10.1016/j.eururo.2008.09.035 ◽

2009 ◽

Vol 55 (1) ◽

pp. 248

Author(s):

Mario A. Eisenberger

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.574906 ◽

2008 ◽

Author(s):

John Amory

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

European Urology ◽

10.1016/j.eururo.2008.08.043 ◽

2008 ◽

Vol 54 (6) ◽

pp. 1438-1439 ◽

Author(s):

Jack A. Schalken

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3062 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3062-3062 ◽

Author(s):

N. Brega ◽

G. A. McArthur ◽

C. Britten ◽

S. G. Wong ◽

E. Wang ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Download Full-text

Phase I Clinical Trial of a Genetically Modified and Oncolytic Vaccinia Virus GL-ONC1 in patients with peritoneal carcinomatosis

Zeitschrift für Gastroenterologie ◽

10.1055/s-0032-1324086 ◽

2012 ◽

Vol 50 (08) ◽

Author(s):

UM Lauer ◽

M Zimmermann ◽

U Koppenhöfer ◽

M Bitzer ◽

NP Malek ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Vaccinia Virus ◽

Peritoneal Carcinomatosis ◽

Genetically Modified ◽

Phase I Clinical Trial

Download Full-text

SAFETY OF A NEW CUBAN PNEUMOCOCCAL CONJUGATE VACCINE: A PHASE I CLINICAL TRIAL IN INFANTS 7 MONTH-OLD

10.26226/morressier.5731f0d7d462b8029237fd99 ◽

2016 ◽

Author(s):

Rinaldo Puga-Gomez

Keyword(s):

Clinical Trial ◽

Phase I ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Phase I Clinical Trial

Download Full-text

Faculty Opinions recommendation of A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718026292.793481389 ◽

2013 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Phase I ◽

Recurrent Ovarian Cancer ◽

Phase I Clinical Trial ◽

Conditionally Replicative Adenovirus

Download Full-text